{"filing":{"accession_number":"0001683168-26-007348","cik":"0000811222","ticker":"CDIX","company_name":"Cardiff Lexington Corp","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"cardiff_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/811222/000168316826007348/cardiff_8k.htm"},"events":[{"id":34738,"run_id":31984,"accession_number":"0001683168-26-007348","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Cardiff Lexington announced entry into a letter of intent for a proposed acquisition of a multi-location musculoskeletal healthcare platform for up to $104 million in aggregate consideration. The press release details the transaction structure, including $30 million cash at closing, $10 million in unsecured notes, preferred equity representing 35% post-closing ownership, and up to $12 million in performance-based common stock. This constitutes a material acquisition activity requiring 8-K disclosure under Item 1.01 or 2.01, disclosed here under Item 8.01 (Other Events).","company_name":"Cardiff Lexington Corp","ticker":"CDIX","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38567,"accession_number":"0001683168-26-007348","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Cardiff Lexington announced entry into a letter of intent for a proposed acquisition of a multi-location musculoskeletal healthcare platform for up to $104 million in aggregate consideration. The press release details the transaction structure, including $30 million cash at closing, $10 million in unsecured notes, preferred equity representing 35% post-closing ownership, and up to $12 million in performance-based common stock. This constitutes a material acquisition activity requiring 8-K disclosure under Item 1.01 or 2.01, disclosed here under Item 8.01 (Other Events).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:01:43.996178+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38567,"accession_number":"0001683168-26-007348","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Cardiff Lexington announced entry into a letter of intent for a proposed acquisition of a multi-location musculoskeletal healthcare platform for up to $104 million in aggregate consideration. The press release details the transaction structure, including $30 million cash at closing, $10 million in unsecured notes, preferred equity representing 35% post-closing ownership, and up to $12 million in performance-based common stock. This constitutes a material acquisition activity requiring 8-K disclosure under Item 1.01 or 2.01, disclosed here under Item 8.01 (Other Events).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T13:01:43.996178+00:00","company_name":"Cardiff Lexington Corp","ticker":"CDIX","filing_date":"2026-09-24"}]}